Potentiation of the immunotherapeutic effect of autologous dendritic cells by pretreating hepatocellular carcinoma with low-dose radiation

Ching-Chung Lin, MD1
Tsang-En Wang, MD1
Chia-Yuan Liu, MD1
Chin-Ping Lin2
Tsang-Pai Liu, MD3
Ming-Jen Chen, MD1
Wen-Hsiung Chang, MD1
Jiunn-Chang Lin, MD1
Kuo-Ming Chang, MD4
Cheng-Hsin Chu, MD1
Shou-Chuan Shih, MD1
K.S. Clifford Chao, MD6
Yu-Jen Chen, MD PhD2,5

1Division of Gastroenterology, 2Department of Medical Research, 3General Surgery, 4Pathology, and 5Radiation Oncology, Mackay Memorial Hospital, Mackay Medicine, Nursing and Management College, Taipei, Taiwan; 6Department of Radiation Oncology, Columbia University, New York, USA.

Manuscript submitted 3rd February, 2008
Manuscript accepted 14th April, 2008

Abstract

Purpose: To determine whether exposing hepatocellular carcinoma (HCC) to low dose radiation increases the efficacy of dendritic cell-mediated immunotherapy for HCC.

Methods: Tumour specimens collected from 20 recruited patients with HCC were cultured in primary culture (half successfully) and then exposed to low-dose radiation (0.5 Gy). Immature DCs derived from peripheral blood monocytes of patients were pulsed with autologous HCC cell lysates and matured with a cytokine cocktail. Autologous tumour lysate-pulsed DCs (TLP-DCs) were used to stimulate mixed lymphocytes, which were then tested for inhibitory effect on the growth of HCC cells. Surface markers of immunogenicity on primary HCC cells, MHC, and Fas were investigated before and after low-dose irradiation.

Results: Exposing HCC cells to low-dose (0.5 Gy) radiation enhanced the immunotherapeutic effect of TLP-DC-stimulated lymphocytes. Growth inhibition increased from 50.6±7.5% without irradiation to 74.3±4.3% with radiation. The expression of MHC class II and Fas was upregulated after irradiating HCC cells.

Conclusion: Exposing tumour cells to a low dose of radiation can enhance the immunotherapeutic effect of the autologous tumor lysate-pulsed DC vaccine.

List of Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>CFSE</td>
<td>Carboxyfluorescin diacetate succinimidyl ester</td>
</tr>
<tr>
<td>CTL</td>
<td>Cytotoxic T-lymphocyte</td>
</tr>
<tr>
<td>DC-SIGN</td>
<td>DC-specific ICAM-grabbing non-integrin</td>
</tr>
<tr>
<td>DC</td>
<td>Dendritic cell</td>
</tr>
<tr>
<td>HCC</td>
<td>Hepatocellular carcinoma</td>
</tr>
<tr>
<td>imDCs</td>
<td>Immature DCs</td>
</tr>
<tr>
<td>MLR</td>
<td>Mixed leukocyte reaction</td>
</tr>
<tr>
<td>NLDC</td>
<td>Normal lymphocytes lysate pulsed DCs</td>
</tr>
<tr>
<td>rhGM-CSF</td>
<td>Recombinant human granulocyte macrophage colony stimulating factor</td>
</tr>
</tbody>
</table>
Dendritic cells (DC) are the most potent antigen-presenting cells in the human body. They are involved in the regulation of both innate and adaptive immune responses. It has been postulated that matured DCs pulsed with tumour-associated antigens may induce cytotoxic T-lymphocytes (CTLs) against tumour cells and thereby inhibit tumor growth. Although preclinical results with tumour vaccines based on this principle are promising, clinical results in patients with advanced solid cancers remain disappointing with response rates less than 15%.

One strategy to improve the DC-mediated immune response is to enhance immunogenicity by exposing the targeted tumour cells to ionizing irradiation. In addition to its direct anti-tumour effect, radiation therapy was shown to increase the presentation of antigens and upregulate the immune response. Recently, the combination of high-dose local tumour radiation (6 to 10 Gy) and adoptive DC immunotherapy has been tested in animal models of pancreatic cancer and melanoma, in sarcoma cell lines, and in patients with advanced liver cancer. While the strategy is appealing, it is not without limitation. First, when disease is advanced or metastatic, localized high dose irradiation is likely only to be palliative, since other tumours outside the radiation field may not be affected. Second, the underlying functional impairment of the host, such as liver cirrhosis, may limit the radiation tolerance of tumour-bearing organs or tissues. Conceivably, if radiation could be delivered to all tumour cells, combining ionizing irradiation with adoptive DC immunotherapy might have greater clinical impact. If proven to be feasible and efficacious, DC-mediated immunotherapy can be used not only in late-stage cancer patients but also to eradicate microscopic metastatic foci before they become clinically evident.

Materials and Methods

Patients and primary cultures

The study protocol was approved by the Institutional Review Board and Ethics Committee. From June 2005 to May 2006, 20 pre-surgical patients with HCC were enrolled in this trial. The specimens of only 10 patients (age, 46–77 yr) were cultured successfully (Table 1). Surgically removed HCC specimens were mashed, digested by DNase and collagenase, and then cultured with RPMI-1640. After two to three passages, autologous HCC tumour cells were harvested and used as the target cells. The characteristics of these autologous HCC tumour cells were compared with those of the original HCC surgical specimen by a pathologist. Hematoxylin and eosin (H&E) stained cells from the primary cultures were oval or polygonal and exhibited nuclear pleomorphism, multiple nuclei, and some mitoses. Some of them were positive for alpha fetoprotein. These characteristics were compatible with the original histological features of HCC (see Supplemental figure 1).

Preparation of tumour lysates

After confirming their identity as tumour cells, they were dispersed into a single-cell suspension (1x10^5 cells/mL), and then lysed by three cycles of snap freeze-thawing. Cell lysis was examined using trypan blue stain, with morphological examination under
light microscopy to ensure no HCC cell remained intact.

**Priming HCC cells with ionizing radiation**

HCC cells were harvested from primary culture and irradiated (0.5 Gy in a single fraction; dose rate, 1.0 Gy/min) using a 6 MeV linear accelerator (Clinac® 1800, Varian Associates, Inc., Palo Alto, CA, USA). Quality assurance of the radiation treatment was carried out using a parallel plate PR-60C ionization chamber (CAPINTEL, Inc., Ramsey, NJ, USA).

**Generation of DCs and morphological observation**

Heparinized peripheral blood was obtained from each patient for preparation of DCs. Leukocytes were isolated by Ficoll-Hypaque density centrifugation and monocytes were purified using magnetic beads conjugated to anti-CD14 and magnetic cell sorting. The harvested CD14+ monocytes were resuspended in RPMI-1640 (Gibco BRL, Gaithersburg, MD, USA). After 2 hr incubation at 37°C, non-adherent cells were removed and the adherent cells were collected and divided into four groups and used as indicated in different experiments. All the cells were cultured for 6 days in medium supplemented with recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF, 100 ng/mL, Schering-Plough, Kenilworth, NJ, USA) and recombinant human interleukin-4 (rhIL-4, 50 ng/mL, R&D Systems Inc. Minneapolis, MN, USA) every 3 days for differentiation to immature DCs. On day 6, immature DCs (imDCs) were further cultured for 24 hr without additional treatment. In the tumour-lysate pulsed cell (TLP-DC) group, immature (im)DCs harvested on day 6 were pulsed with autologous tumour lysate for 24 hr and matured with a DC maturation-triggering cytokine cocktail including IL-1β (5 ng/mL; R&D Systems Inc.), IL-6 (15 ng/mL; R&D Systems), TNF-α (5 ng/mL; R&D Systems), and prostaglandin E2 (1 μg/mL; Sigma, St Louis, MO, USA). In the unpulsed DC group (UP-DC), imDCs were cultured with the cytokine cocktail without tumour lysate pulsing. In some experiments, imDCs were pulsed with normal lymphocyte lysates (NL-DC) and exposed to cytokine cocktail to compare with those pulsed with tumor-lysate. For morphological assessment, DCs were stained with Liu stain and observed under a light microscope.

**Analysis of surface marker expression on DCs and primary HCC tumor cells**

Dual-colour immunolabelling was performed using fluorescein isothiocyanate (FITC)- and phycoerythrin (PE)-conjugated monoclonal antibodies (mAbs). The mouse anti-human mAbs IgG1:FITC/mouse IgG1:PE,
and appropriate isotype controls were purchased from Serotec (Oxford, UK) and used for DC characterization as follows: anti-CD14 (for IgG-FITC), anti-CD83-PE, anti-HLA-DR-PE, and anti-DC-SIGN-PE. For analysis of tumour cells, anti-MHC class I-FITC, anti-HLA-DR-PE, and anti-Fas-PE were used. Prior to fluorocytometric analysis, cells were incubated with saturating concentrations of PE-conjugated mAbs and primary CD11c mAbs followed by IgG-FITC at 4°C for 30 minutes. After washing twice with PBS, 1x10^6 cells were applied to a FACScaliber flow cytometer (BD Biosciences, San Jose, CA, USA). Data were collected and analyzed using CellQuest Software (BD Biosciences).

**Autologous mixed lymphocyte reaction to DCs stimulation**

To isolate mixed lymphocytes, mononuclear cells from human peripheral blood were separated by centrifugation on a density gradient (Ficoll-Hypaque, 1.077 gm/mL, Pharmacia Fine Chemicals, Piscataway, NJ, USA). After 2-hr incubation, the non-adherent cells were harvested and re-suspended in RPMI 1640 medium (GIBCO, Grand Island, NY, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Hyclone, Logan, UT, USA) and penicillin/streptomycin. Prior to co-culturing with mixed lymphocytes, DCs were irradiated with 30 Gy to stop proliferation and limit a potential confounding factor that might influence the primary objective (lymphocyte numbers) of this experiment. Irradiated DCs (10,000 cells) and mixed lymphocytes were co-cultured and stained with carboxyfluorescein diacetate succinimidyl ester (CFSE). After 4 days of culture, the mean fluorescence intensity of the cells was measured and analyzed by flow cytometry to determine the extent of proliferation of mixed lymphocytes.

**Fluorescence microscopy**

PKH 67 green fluorescence cell linker kit (Sigma-Aldrich, Inc., St Louis, MO, USA) was used to label tumour lysate 24 hr before pulsing of immature DCs. DCs were stained with PE-labeled anti-DC-SIGN mAb for discrimination during observation under a fluorescence microscope. Microphotos were taken at 400 X magnification.

**Viability of HCC cells**

Mixed lymphocytes (1x10^6 cells/mL, 1 mL) were co-cultured with irradiated autologous TLP-DCs, UP-DCs, or NL-DCs (1x10^6 cells/mL, 100 μL) for 24 hr and then subjected to co-culture with unirradiated or 0.5 Gy-irradiated autologous primary cultured HCC cells (1x10^6 cells/mL, 1 mL) for 4 days. The growth-inhibitory activity of DC-stimulated mixed lymphocytes against primary HCC cells was estimated using the trypan blue exclusion test or by the MTT assay. The tumour inhibition rate was calculated using the following formula: (1-[live tumor cells after reaction/live tumour cells before reaction]) x 100 %.

**Statistical analysis**

All data are presented as mean ± SEM. Differences among groups were determined with one-way ANOVA followed by the Tukey test. The changes in surface molecule expression with and without low dose RT exposure were determined by a paired t-test using the statistical software package SigmaStat 3.0. The level of statistical significance was set at $P < 0.05$.

**Results**

**Morphology of DCs and uptake of tumor lysates**

The monocyte-derived cells had multiple long cytoplasmic extensions characteristic for DCs. After staining with PE-DC-SIGN and culture with PKH67-labelled tumor lysates, UP-DCs only showed red fluorescence on the cell surface (Figure 1A), whereas TLP-DCs had red fluorescence on the surface as well as green fluorescence in the cytoplasm (Figure 1B).
This indicates that TLP-DCs had taken up the tumor lysates.

**Surface marker expression of immature and mature DCs**

DCs differentiated from monocytes with or without stimulation with maturation-triggering cytokine cocktail expressed low levels of CD14 (a monocyte/macrophage marker) and high levels of HLA-DR (a MHC class II molecule). The percentage of CD14-expressing imDCs, UP-DCs, and TLP-DCs was 2.2 ± 0.5%, 2.8 ± 0.8%, and 11.5 ± 4.9%, respectively. On the other hand, the percentage of cells positive for HLA-DR was 55.8 ± 15.0%, 73.6 ± 14.1%, and 71.1 ± 11.6%, respectively. CD83 is a well-known surface marker of mature DCs and its expression rate in imDCs was only 14.6 ± 2.5%. However, it increased to 64.4 ± 2.6% (P < 0.05) after stimulation with maturation-triggering cytokine cocktail (UP-DCs). Although tumor cells may release immunosuppressive cytokine and might interfere with DC maturation, in our study, tumor lysate did not interfere the CD83 expression (66.2 ± 10.3% in TLP-DCs). The comparable CD83 expression between UP-DCs and TLP-DCs indicates that pulsing with tumor lysate did not interfere with DC maturation (Figure 2, Supplemental figure 2).

**Tumor lysate-pulsed DCs stimulated mixed lymphocyte proliferation**

Of the four kinds of DCs, including the normal lymphocyte lysate-pulsed DCs (with degree of stimulation 1.3 times that of the control DCs, data not shown), tumor lysate-pulsed DCs stimulated mixed lymphocyte proliferation to the greatest degree (1.6 times that of the control DCs). This indicates that TLP-DCs were the most auto-stimulatory.

**Cytotoxic effect of DC-mediated lymphocytes against primary HCC cells**

Lymphocytes cultured with TLP-DCs inhibited the growth of autologous HCC cells to a much greater extent than lymphocytes cultured with the other types of DCs (50.6 ± 7.5% inhibition vs. 8.1 ± 11.7% with untreated lymphocytes, 1.7 ± 8.4% with UPDCs, and 10.2 ± 7.6% with NLDCs) (Figure 3). It suggests that the autologous TLP-DCs have immunotherapeutic effects on primary cultured HCC cells through the action of lymphocytes; although greater than that of the other types of DCs, the efficacy of TLP-DCs (50.6 ± 7.5% inhibition) was only moderate.

**Enhancement of immunotherapeutic effect by low dose radiation to HCC cells**

Low dose radiation (0.5 Gy) had no effect on the growth of autologous HCC cells and, as mentioned above, lymphocytes cultured with TLP-DCs inhibited growth of autologous HCC cells (50.6 ± 7.5% growth inhibition). However, preirradiating autologous HCC cells with 0.5 Gy sensitized them to TLP-DCs-mediated cytolytic activity (74.3 ± 4.3% growth inhibition) (Figure 3).

**Induction of cell surface marker expression by low dose irradiation**

The surface expression of MHC class I, MHC class II, and cell death receptor Fas on tumor with or without low dose radiation were examined. As shown in figure...
4 and supplemental figure 3, low dose radiation augmented the surface expression of MHC class II and Fas.

Discussion

We successfully used rhGM-CSF and rhIL-4 to trigger monocyte differentiation into DCs with markedly increased HLA-DR expression. GM-CSF and IL-4 are often used to induce peripheral blood mononuclear cells to differentiate into DCs. IL-4-treated DCs have high endocytic activity and induce efficiently allogeneic T-cell proliferation.\(^{13}\) These immature DCs were further matured by a cytokine cocktail on day 7, with an increase in CD83 (a marker of mature DC) expression from 12% to 62%. Although, previous reports have suggested that DCs are functionally defective in patients with cancer,\(^{14,15}\) in the current study, we successfully induced maturation of DCs using the peripheral blood mononuclear cells collected from patients with HCC. We further demonstrated that autologous tumour lysate-pulsed DCs effectively stimulate mixed lymphocytes to inhibit the growth of autologous primary HCC cells. Pretreating HCC cells with low dose radiation further enhanced the immunotherapeutic efficacy of tumor lysate-pulsed DCs.

We found TLP-DCs could engulf tumour cell fragments, as demonstrated by uptake of PKH 67-labeled tumour lysates by DCs (Figure 1B). Uptake of tumour lysate proteins, processing of the proteins, and presentation of the tumour-associated antigens by DCs, are all necessary for stimulation and activation of T lymphocytes. The exact route of antigen uptake after phagocytosis of cell fragments is unclear. Proposed mechanisms include involvement of MHC class
l and II molecules\textsuperscript{16} or uptake via specific receptors such as DC-SIGN\textsuperscript{17} or FcγR\textsuperscript{18}.

One approach to increase tumour immunogenicity is to treat tumour cells with high-dose radiation (6-10 Gy or more) to induce tumour cell death. The resulting debris serves as the source of cancer cell antigens to be taken up by DCs that subsequently present them to the immune system.\textsuperscript{19} This is presumed to be the reason that the combination of RT and DC immunotherapy showed antitumour effect in some studies.\textsuperscript{8,20,21} While the strategy is appealing, there are some problems. First, the underlying functional impairment of the host may limit the radiation tolerance of tumor-bearing organs or tissues. In particular, HCC patients commonly have underlying hepatic diseases such as chronic hepatitis and liver cirrhosis. Second, when their disease is already advanced or metastatic, localized high dose irradiation is likely only to be palliative, since other tumours outside the radiation field may not be affected. If radiation can be delivered to all tumour foci, the approach of priming the tumours with ionizing irradiation followed by adoptive DC immunotherapy will have a much broader clinical impact including even eradication of microscopic metastatic cancer cells before they become clinically evident.

In our study, the low dose of radiation did not decrease the viability of HCC cells. We also failed to observe any obvious changes in HCC cell morphology related to apoptosis, necrosis, or mitotic catastrophe (data not shown). Thus, cell death might not be induced by such low dose of radiation.

The auto-stimulatory effect of T-cells was only noted in DCs pulsed with tumor lysates but not in DCs pulsed with normal lymphocyte lysates. These findings provide evidence that this approach acts through a tumour-specific mechanism. We further investigated how low-dose (0.5 Gy) radiation increased the anti-tumour effect of TLP-DCs and found increased Fas and MHC class II expression on the surface of HCC cells after 0.5 Gy. Fas is a member of the death receptor family, which is involved in the extrinsic apoptotic pathway. Furthermore, tumour cells may be hypersensitive to low-dose radiation, an effect associated with translocation of phosphatidylserine and p53-dependent apoptosis.\textsuperscript{22} Increase in expression of Fas by ionizing radiation has been reported to correlate with increased in cellular sensitivity to apoptosis.\textsuperscript{23} Radiation at a higher dose (10 – 18 Gy) has been reported to enhance the expression of MHC class II on myeloma and ovarian cancer cells, and this enhancement is considered to increase the immunogenicity of the tumour cells.\textsuperscript{24} One report demonstrated that two radiation fractions of 4 Gy could upregulate MHC class I expression on invasive glioma GL261 cells. This up-regulation of MHC-I molecule expression might explain why whole brain radiotherapy enhances the effectiveness of immunotherapy in vivo.\textsuperscript{25} One may speculate that surface expression of MHC class II and Fas after low dose radiation, as observed in the current study, may have contributed to the increase in immune response of tumour lysate-pulsed DCs to HCCs by increasing not only immunogenicity and consequent recruitment of effector T-cells but also susceptibility to Fas-mediated cell death, so we are on going to test these mechanism in an animal model.

**Conclusions**

We have demonstrated that autologous TLP-DCs maintain the ability to stimulate an autologous tumour-specific mixed lymphocyte reaction that inhibits growth of autologous HCC cells. Priming HCC cells with low-dose irradiation enhanced the immunotherapeutic effect of the TLP-DCs vaccine, which may in part be attributed to the increase in MHC class II and Fas expression on HCC cells.

**Acknowledgments**

Supported by Grant No. MMH-E-95006 and MMH-I-S-166 from the Mackay Memorial Hospital.
References

Correspondence to:

Dr. Yu-Jen Chen,
Department of Radiation Oncology,
Mackay Memorial Hospital,
92 Chung San North Road, Section 2,
Taipei 104, Taiwan.
E-mail: chenmdphd@yahoo.com
or to: Dr. K. S. Clifford Chao
Department of Radiation Oncology,
Columbia University, New York
E-mail: cchao@mdanderson.org

SUPPLEMENTAL FIGURE 1. A representative case (No. 2 patient) showing morphology and immunohistochemical stain of hepatoma tissue and primary cultured cells. (A – B, H&E stain for tumor tissue; C – D, H&E stain for cultured cells; E, immunohistochemical stain of AFP for cultured cells. Magnification: 250 X for A and C, 400 for B and D, and 1000 X for E.)
SUPPLEMENTAL FIGURE 2. Flowcytometric histogram for surface markers of DCs from case 2.

SUPPLEMENTAL FIGURE 3. Flowcytometric histogram for surface markers of HCC cells from case 2.